William G Hawkins

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/999069/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Improved outcomes with minimally invasive pancreaticoduodenectomy in patients with dilated pancreatic ducts: a prospective study. Surgical Endoscopy and Other Interventional Techniques, 2022, 36, 3100-3109.	1.3	4
2	Development of a Prognostic Nomogram and Nomogram Software Application Tool to Predict Overall Survival and Disease-Free Survival After Curative-Intent Gastrectomy for Gastric Cancer. Annals of Surgical Oncology, 2022, 29, 1220-1229.	0.7	8
3	Cause and outcome of aborting a difficult laparoscopic cholecystectomy due to severe inflammation: a study of operative notes. Surgical Endoscopy and Other Interventional Techniques, 2022, , 1.	1.3	0
4	The targeted SMAC mimetic SW IV-134 augments platinum-based chemotherapy in pre-clinical models of ovarian cancer. BMC Cancer, 2022, 22, 263.	1.1	3
5	Clinical classification of symptomatic heterotopic pancreas of the stomach and duodenum: A case series and systematic literature review. World Journal of Gastroenterology, 2022, 28, 1455-1478.	1.4	11
6	Qualitative imaging features of pancreatic neuroendocrine neoplasms predict histopathologic characteristics including tumor grade and patient outcome. Abdominal Radiology, 2022, 47, 3971-3985.	1.0	2
7	Oncogenic Kras-Mediated Cytokine CCL15 Regulates Pancreatic Cancer Cell Migration and Invasion through ROS. Cancers, 2022, 14, 2153.	1.7	5
8	ASO Visual Abstract: Increased Morbidity and Mortality After Hepatectomy for Colorectal Liver Metastases in Frail Patients is Largely Driven by Worse Outcomes After Minor Hepatectomy: It is Not "Just a Wedge― Annals of Surgical Oncology, 2022, , 1.	0.7	0
9	Oligometastatic Rectal Adenocarcinoma Treated With Short-Course Radiation Therapy and Chemotherapy With Nonoperative Intent of the Primary for Locoregional Complete Responders. Practical Radiation Oncology, 2022, 12, e406-e414.	1.1	1
10	Less is more in the difficult gallbladder: recent evolution of subtotal cholecystectomy in a single HPB unit. Surgical Endoscopy and Other Interventional Techniques, 2021, 35, 3249-3257.	1.3	23
11	Regional Variation in Unmet Need for Metabolic Surgery in England: a Retrospective, Multicohort Analysis. Obesity Surgery, 2021, 31, 439-444.	1.1	3
12	Feasibility and safety of non-operative management of portal vein aneurysms: a thirty-five year experience. Hpb, 2021, 23, 127-133.	0.1	6
13	Ablative Five-Fraction Stereotactic Body Radiation Therapy for Inoperable Pancreatic Cancer Using Online MR-Guided Adaptation. Advances in Radiation Oncology, 2021, 6, 100506.	0.6	70
14	Elucidating the Efficacy of Pancreatectomy for Renal Cell Metastases Remains Problematic. Annals of Surgical Oncology, 2021, 28, 2946-2948.	0.7	0
15	Predicting Outcomes in Patients Undergoing Pancreatectomy Using Wearable Technology and Machine Learning: Prospective Cohort Study. Journal of Medical Internet Research, 2021, 23, e23595.	2.1	26
16	Systematic Review and Meta-Analysis of the Impact of Bariatric Surgery on Lower Urinary Tract Symptoms in Males. Obesity Surgery, 2021, 31, 3151-3158.	1.1	4
17	Inability to manage non-severe complications on an outpatient basis increases non-white patient readmission rates after pancreaticoduodenectomy: A large metropolitan tertiary care center experience. American Journal of Surgery, 2021, 222, 964-968.	0.9	3
18	Re-defining a high volume center for pancreaticoduodenectomy. Hpb, 2021, 23, 733-738.	0.1	26

#	Article	IF	CITATIONS
19	Enhanced recovery pathway after open pancreaticoduodenectomy reduces postoperative length of hospital stay without reducing composite length of stay. Hpb, 2021, , .	0.1	1
20	Care Fragmentation and Mortality in Readmission after Surgery for Hepatopancreatobiliary and Gastric Cancer: A Patient-Level and Hospital-Level Analysis of the Healthcare Cost and Utilization Project Administrative Database. Journal of the American College of Surgeons, 2021, 232, 921-932e12.	0.2	11
21	ASO Visual Abstract: Development of a Prognostic Nomogram and Nomogram Software Application Tool to Predict Overall Survival and Disease-Free Survival After Curative-Intent Gastrectomy for Gastric Cancer. Annals of Surgical Oncology, 2021, 28, 734-735.	0.7	5
22	Neoadjuvant FOLFIRINOX Therapy Is Associated with Increased Effector T Cells and Reduced Suppressor Cells in Patients with Pancreatic Cancer. Clinical Cancer Research, 2021, 27, 6761-6771.	3.2	33
23	Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, 439-457.	2.3	564
24	Hepatobiliary Cancers, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, 541-565.	2.3	477
25	Assessment of Hepatic Arterial Infusion of Floxuridine in Combination With Systemic Gemcitabine and Oxaliplatin in Patients With Unresectable Intrahepatic Cholangiocarcinoma. JAMA Oncology, 2020, 6, 60.	3.4	112
26	Composite Length of Stay, An Outcome Measure of Postoperative and Readmission Length of Stays in Pancreatoduodenectomy. Journal of Gastrointestinal Surgery, 2020, 24, 2062-2069.	0.9	10
27	A 22-year experience with pancreatic resection for metastatic renal cell carcinoma. Hpb, 2020, 22, 312-317.	0.1	11
28	Increased Mutational Burden Sensitizes Pancreatic Cancer to Anti-Tumor Effects of Immunotherapy. Journal of the American College of Surgeons, 2020, 231, S161-S162.	0.2	0
29	Tumor-insular Complex in Neoadjuvant Treated Pancreatic Ductal Adenocarcinoma Is Associated With Higher Residual Tumor. American Journal of Surgical Pathology, 2020, 44, 817-825.	2.1	1
30	The clonal evolution of metastatic colorectal cancer. Science Advances, 2020, 6, eaay9691.	4.7	41
31	Dendritic Cell Paucity Leads to Dysfunctional Immune Surveillance in Pancreatic Cancer. Cancer Cell, 2020, 37, 289-307.e9.	7.7	252
32	Sutures, ligatures and knots. Surgery, 2020, 38, 123-127.	0.1	0
33	Intratumoral Fibrosis and Tumor Growth Pattern as Prognostic Factors in Optimally Resected Pancreatic Neuroendocrine Neoplasms. Pancreas, 2020, 49, 255-260.	0.5	11
34	B cell–Derived IL35 Drives STAT3-Dependent CD8+ T-cell Exclusion in Pancreatic Cancer. Cancer Immunology Research, 2020, 8, 292-308.	1.6	62
35	Accuracy of Grading in Pancreatic Neuroendocrine Neoplasms and Effect on Survival Estimates: An Institutional Experience. Annals of Surgical Oncology, 2020, 27, 3542-3550.	0.7	6
36	Thunderbeatâ,,¢ Integrated Bipolar and Ultrasonic Forceps in the Whipple Procedure: A Prospective Randomized Trial. Missouri Medicine, 2020, 117, 559-562.	0.3	0

#	Article	IF	CITATIONS
37	S0954 Compliance With ASGE Quality Indicators for Endoscopic Ultrasound Reports in the Evaluation of Pancreatic Cancer: Comparison of Community and Academic Practices. American Journal of Gastroenterology, 2020, 115, S488-S489.	0.2	0
38	Extending Enhanced Recovery after Surgery Protocols to the Post-Discharge Setting: A Phone Call Intervention to Support Patients after Expedited Discharge after Pancreaticoduodenectomy. American Surgeon, 2020, 86, 42-48.	0.4	5
39	Association of preoperative monocyteâ€toâ€lymphocyte and neutrophilâ€toâ€lymphocyte ratio with recurrenceâ€free and overall survival after resection of pancreatic neuroendocrine tumors (USâ€NETSG). Journal of Surgical Oncology, 2019, 120, 632-638.	0.8	30
40	Agonism of CD11b reprograms innate immunity to sensitize pancreatic cancer to immunotherapies. Science Translational Medicine, 2019, 11, .	5.8	148
41	T Cell– and Monocyte-Specific RNA-Sequencing Analysis in Septic and Nonseptic Critically III Patients and in Patients with Cancer. Journal of Immunology, 2019, 203, 1897-1908.	0.4	38
42	Long-Term Endocrine and Exocrine Insufficiency After Pancreatectomy. Journal of Gastrointestinal Surgery, 2019, 23, 1604-1613.	0.9	47
43	TMEM97 and PGRMC1 do not mediate sigma-2 ligand-induced cell death. Cell Death Discovery, 2019, 5, 58.	2.0	43
44	Arginine Starvation and Docetaxel Induce c-Myc–Driven hENT1 Surface Expression to Overcome Gemcitabine Resistance in ASS1-Negative Tumors. Clinical Cancer Research, 2019, 25, 5122-5134.	3.2	47
45	National Pancreatic Fistula Rates after Minimally Invasive Pancreaticoduodenectomy: A NSQIP Analysis. Journal of the American College of Surgeons, 2019, 229, 192-199e1.	0.2	17
46	Survival Outcomes Associated With Clinical and Pathological Response Following Neoadjuvant FOLFIRINOX or Gemcitabine/Nab-Paclitaxel Chemotherapy in Resected Pancreatic Cancer. Annals of Surgery, 2019, 270, 400-413.	2.1	113
47	Pancreas Cancer-Associated Weight Loss. Oncologist, 2019, 24, 691-701.	1.9	99
48	Precision delivery of RAS-inhibiting siRNA to KRAS driven cancer via peptide-based nanoparticles. Oncotarget, 2019, 10, 4761-4775.	0.8	45
49	Guidelines Insights: Pancreatic Adenocarcinoma, Version 1.2019. Journal of the National Comprehensive Cancer Network: JNCCN, 2019, 17, 202-210.	2.3	281
50	Guidelines Insights: Hepatobiliary Cancers, Version 2.2019. Journal of the National Comprehensive Cancer Network: JNCCN, 2019, 17, 302-310.	2.3	214
51	IL23 and TGF-ß diminish macrophage associated metastasis in pancreatic carcinoma. Scientific Reports, 2018, 8, 5808.	1.6	16
52	Optimal extent of surgical and pathologic lymph node evaluation for resected intrahepatic cholangiocarcinoma. Hpb, 2018, 20, 470-476.	0.1	11
53	Epidurals in Pancreatic Resection Outcomes (E-PRO) study: protocol for a randomised controlled trial. BMJ Open, 2018, 8, e018787.	0.8	3
54	Outcomes after vascular resection during curative-intent resection for hilar cholangiocarcinoma: a multi-institution study from the US extrahepatic biliary malignancy consortium. Hpb, 2018, 20, 332-339.	0.1	27

#	Article	IF	CITATIONS
55	Adjuvant therapy is associated with improved survival after curative resection for hilar cholangiocarcinoma: A multiâ€institution analysis from the U.S. extrahepatic biliary malignancy consortium. Journal of Surgical Oncology, 2018, 117, 363-371.	0.8	36
56	Utility of Endoscopic Ultrasound in Evaluating Local RecurrenceÂAfter Surgery for Pancreatic Cancer. Clinical Gastroenterology and Hepatology, 2018, 16, 1834-1835.	2.4	1
57	Breast and pancreatic cancer interrupt IRF8-dependent dendritic cell development to overcome immune surveillance. Nature Communications, 2018, 9, 1250.	5.8	151
58	Multifunctional thiosemicarbazones and deconstructed analogues as a strategy to study the involvement of metal chelation, Sigma-2 (σ2) receptor and P-gp protein in the cytotoxic action: InÂvitro and inÂvivo activity in pancreatic tumors. European Journal of Medicinal Chemistry, 2018, 144, 359-371.	2.6	33
59	Targeting both tumour-associated CXCR2 ⁺ neutrophils and CCR2 ⁺ macrophages disrupts myeloid recruitment and improves chemotherapeutic responses in pancreatic ductal adenocarcinoma. Gut, 2018, 67, 1112-1123.	6.1	334
60	Surgeon Variation in Intraoperative Supply Cost for Pancreaticoduodenectomy: Is Intraoperative Supply Cost Associated with Outcomes?. Journal of the American College of Surgeons, 2018, 226, 37-45e1.	0.2	7
61	Prospective Evaluation of Pasireotide in Patients Undergoing Pancreaticoduodenectomy: The Washington University Experience. Journal of the American College of Surgeons, 2018, 226, 147-154e1.	0.2	19
62	Residual Tumor Index. American Journal of Surgical Pathology, 2018, 42, 1480-1487.	2.1	18
63	Recruitment of CCR2 ⁺ tumor associated macrophage to sites of liver metastasis confers a poor prognosis in human colorectal cancer. OncoImmunology, 2018, 7, e1470729.	2.1	88
64	Long term exocrine and endocrine function after pancreatectomy. Hpb, 2018, 20, S44-S45.	0.1	1
65	<i>The Hand-Assisted Laparoscopic Approach to Resection of Pancreatic Mucinous Cystic Neoplasms: An Underused Technique?</i> . American Surgeon, 2018, 84, 56-62.	0.4	3
66	The importance of early recognition in management of ERCP-related perforations. Surgical Endoscopy and Other Interventional Techniques, 2018, 32, 4841-4849.	1.3	15
67	Synoptic operative reporting for laparoscopic cholecystectomy and pancreaticoduodenectomy: A multi institutional pilot study evaluating completeness and surgeon perceptions. American Journal of Surgery, 2018, 216, 935-940.	0.9	9
68	The Hand-Assisted Laparoscopic Approach to Resection of Pancreatic Mucinous Cystic Neoplasms: An Underused Technique?. American Surgeon, 2018, 84, 56-62.	0.4	0
69	Whipple-specific complications result in prolonged length of stay not accounted for in ACS-NSQIP Surgical Risk Calculator. Hpb, 2017, 19, 147-153.	0.1	36
70	Utility of a multidisciplinary tumor board in the management of pancreatic and upper gastrointestinal diseases: an observational study. Hpb, 2017, 19, 133-139.	0.1	54
71	The diagnosis of pancreatic mucinous cystic neoplasm and associated adenocarcinoma in males: An eightâ€institution study of 349 patients over 15 years. Journal of Surgical Oncology, 2017, 115, 784-787.	0.8	15
72	Sutures, ligatures and knots. Surgery, 2017, 35, 185-189.	0.1	4

#	Article	IF	CITATIONS
73	Gallbladder Cancer Presenting with Jaundice: Uniformly Fatal or Still Potentially Curable?. Journal of Gastrointestinal Surgery, 2017, 21, 1245-1253.	0.9	30
74	NCCN Guidelines Insights: Hepatobiliary Cancers, Version 1.2017. Journal of the National Comprehensive Cancer Network: JNCCN, 2017, 15, 563-573.	2.3	272
75	Impact of lymph node ratio in selecting patients with resected gastric cancer for adjuvant therapy. Surgery, 2017, 162, 285-294.	1.0	25
76	Interferon-based chemoradiation followed by gemcitabine for resected pancreatic adenocarcinoma: long-term follow-up. Hpb, 2017, 19, 449-457.	0.1	10
77	Pattern of Venous Collateral Development after Splenic Vein Occlusion in an Extended Whipple Procedure (Whipple at the Splenic Artery) and Long-Term Results. Journal of Gastrointestinal Surgery, 2017, 21, 516-526.	0.9	35
78	Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2017, 15, 1028-1061.	2.3	762
79	Diagnosis and management of biliary injuries. Current Problems in Surgery, 2017, 54, 406-435.	0.6	13
80	Tissue-Resident Macrophages in Pancreatic Ductal Adenocarcinoma Originate from Embryonic Hematopoiesis and Promote Tumor Progression. Immunity, 2017, 47, 323-338.e6.	6.6	499
81	Flange Gastroenterostomy Results in Reduction in Delayed Gastric Emptying after Standard Pancreaticoduodenectomy: A Prospective Cohort Study. Journal of the American College of Surgeons, 2017, 225, 498-507.	0.2	19
82	Sigma-2 receptor agonist derivatives of 1-Cyclohexyl-4-[3-(5-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)propyl]piperazine (PB28) induce cell death via mitochondrial superoxide production and caspase activation in pancreatic cancer. BMC Cancer, 2017, 17, 51.	1.1	37
83	Association of Preoperative Risk Factors With Malignancy in Pancreatic Mucinous Cystic Neoplasms. JAMA Surgery, 2017, 152, 19.	2.2	82
84	Intensity modulated radiation therapy and surgery for Management of Retroperitoneal Sarcomas: a single-institution experience. Radiation Oncology, 2017, 12, 198.	1.2	13
85	Precision delivery of RAS-inhibiting siRNA to pancreatic cancer via peptide-based nanoparticles Journal of Clinical Oncology, 2017, 35, 287-287.	0.8	2
86	Targeting inflammatory monocytes in human metastatic colorectal cancer Journal of Clinical Oncology, 2017, 35, 605-605.	0.8	16
87	Phase I study of defactinib combined with pembrolizumab and gemcitabine in advanced cancer Journal of Clinical Oncology, 2017, 35, TPS505-TPS505.	0.8	2
88	Adenovirus platform enhances transduction efficiency of human mesenchymal stem cells: An opportunity for cellular carriers of targeted TRAIL-based TR3 biologics in ovarian cancer. PLoS ONE, 2017, 12, e0190125.	1.1	14
89	Analysis of the effect of adjuvant therapy on overall survival for resected gallbladder adenocarcinoma using the National Cancer Database Journal of Clinical Oncology, 2017, 35, 360-360.	0.8	0
90	Targeted pancreatic cancer drug-delivery utilizing sigma-2 ligand/receptor internalization is energy-dependent Journal of Clinical Oncology, 2017, 35, 331-331.	0.8	0

#	Article	IF	CITATIONS
91	Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy. Nature Medicine, 2016, 22, 851-860.	15.2	738
92	Single institution results of radical antegrade modular pancreatosplenectomy for adenocarcinoma of the body and tail of pancreas in 78 patients. Journal of Hepato-Biliary-Pancreatic Sciences, 2016, 23, 432-441.	1.4	38
93	Timing of Surgical Repair After Bile Duct Injury Impacts Postoperative Complications but Not Anastomotic Patency. Annals of Surgery, 2016, 264, 544-553.	2.1	64
94	Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial. Lancet Oncology, The, 2016, 17, 651-662.	5.1	557
95	The management of bariatric surgery complications. Surgery, 2016, 34, 563-567.	0.1	0
96	Operative Site Drainage after Hepatectomy: A Propensity Score Matched Analysis Using the American College of Surgeons NSQIP Targeted Hepatectomy Database. Journal of the American College of Surgeons, 2016, 223, 774-783e2.	0.2	25
97	Membrane-proximal TRAIL species are incapable of inducing short circuit apoptosis signaling: Implications for drug development and basic cytokine biology. Scientific Reports, 2016, 6, 22661.	1.6	6
98	Interaction of Postoperative Morbidity and Receipt of Adjuvant Therapy on Long-Term Survival After Resection for Gastric Adenocarcinoma: Results From the U.S. Gastric Cancer Collaborative. Annals of Surgical Oncology, 2016, 23, 2398-2408.	0.7	63
99	Perception Is Reality: quality metrics in pancreas surgery – a Central Pancreas Consortium (CPC) analysis of 1399 patients. Hpb, 2016, 18, 462-469.	0.1	8
100	Induction Chemotherapy Followed by Concurrent Full-dose Gemcitabine and Intensity-modulated Radiation Therapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2016, 39, 1-7.	0.6	24
101	Mesothelin's minimal MUC16 binding moiety converts TR3 into a potent cancer therapeutic <i>via</i> hierarchical binding events at the plasma membrane. Oncotarget, 2016, 7, 31534-31549.	0.8	12
102	Conjugation to the sigma-2 ligand SV119 overcomes uptake blockade and converts dm-Erastin into a potent pancreatic cancer therapeutic. Oncotarget, 2016, 7, 33529-33541.	0.8	21
103	Radioprotective properties of myeloid-derived suppressor cells. Translational Cancer Research, 2016, 5, S923-S925.	0.4	1
104	Curative resection for hilar cholangiocarcinoma: Does adjuvant therapy impact overall survival? A multi-institution analysis from the U.S. Extrahepatic Biliary Malignancy Consortium Journal of Clinical Oncology, 2016, 34, 388-388.	0.8	0
105	A reappraisal of staging laparoscopy in three subtypes of cholangiocarcinoma: A multi-institution analysis from the U.S. Extrahepatic Biliary Malignancy Consortium Journal of Clinical Oncology, 2016, 34, 226-226.	0.8	0
106	A multi-center study of 349 pancreatic mucinous cystic neoplasms: Preoperative risk factors for adenocarcinoma Journal of Clinical Oncology, 2016, 34, 231-231.	0.8	0
107	Natural History of Preoperative Subcentimeter Pulmonary Nodules in Patients With Resectable Pancreatic Adenocarcinoma. Annals of Surgery, 2015, 261, 970-975.	2.1	22
108	Cost variation in a laparoscopic cholecystectomy and the association with outcomes across a single health system: implications for standardization and improved resource utilization. Hpb, 2015, 17, 1113-1118.	0.1	21

#	Article	IF	CITATIONS
109	Factors Associated With Recurrence and Survival in Lymph Node–negative Gastric Adenocarcinoma. Annals of Surgery, 2015, 262, 999-1005.	2.1	40
110	Prognostic Performance of Different Lymph Node Staging Systems After Curative Intent Resection for Gastric Adenocarcinoma. Annals of Surgery, 2015, 262, 991-998.	2.1	83
111	Incorporation of Porcine Adenovirus 4 Fiber Protein Enhances Infectivity of Adenovirus Vector on Dendritic Cells: Implications for Immune-Mediated Cancer Therapy. PLoS ONE, 2015, 10, e0125851.	1.1	7
112	The impact of recent hospitalization on surgical site infection after a pancreatectomy. Hpb, 2015, 17, 819-823.	0.1	6
113	A Nomogram to Predict Overall Survival and Disease-Free Survival After Curative Resection of Gastric Adenocarcinoma. Annals of Surgical Oncology, 2015, 22, 1828-1835.	0.7	62
114	Improved peri-operative outcomes with epidural analgesia in patients undergoing a pancreatectomy: a nationwide analysis. Hpb, 2015, 17, 551-558.	0.1	23
115	Regramming myeloid responses to improve cancer immunotherapy. Oncolmmunology, 2015, 4, e974399.	2.1	9
116	Conditional Survival after Surgical Resection of Gastric Cancer: A Multi-Institutional Analysis of the US Gastric Cancer Collaborative. Annals of Surgical Oncology, 2015, 22, 557-564.	0.7	61
117	The role of inflammatory monocytes in human metastatic colorectal cancer Journal of Clinical Oncology, 2015, 33, 624-624.	0.8	3
118	Targeting tumor infiltrating myeloid cells to inhibit tumor progression in pancreatic adenocarcinoma Journal of Clinical Oncology, 2015, 33, e15217-e15217.	0.8	0
119	Value of Intraoperative Neck Margin Analysis During Whipple for Pancreatic Adenocarcinoma. Annals of Surgery, 2014, 260, 494-503.	2.1	88
120	Conjugation to a SMAC mimetic potentiates sigma-2 ligand induced tumor cell death in ovarian cancer. Molecular Cancer, 2014, 13, 50.	7.9	24
121	Regional Lymphadenectomy Is Indicated in the Surgical Treatment of Pancreatic Neuroendocrine Tumors (PNETs). Annals of Surgery, 2014, 259, 197-203.	2.1	213
122	Targeted pancreatic cancer therapy with the small molecule drug conjugate SW IVâ€134. Molecular Oncology, 2014, 8, 956-967.	2.1	38
123	Jaundice: an important, poorly recognized risk factor for diminished survival in patients with adenocarcinoma of the head of the pancreas. Hpb, 2014, 16, 150-156.	0.1	54
124	A New Operative Approach for Type I Choledochal Cysts. Journal of Gastrointestinal Surgery, 2014, 18, 1049-1053.	0.9	4
125	Severe Nutritional Risk Predicts Decreased Long-Term Survival in Geriatric Patients Undergoing Pancreaticoduodenectomy for Benign Disease. Journal of the American College of Surgeons, 2014, 219, 1149-1156.	0.2	20
126	Association of Discharge Home with Home Health Care and 30-Day Readmission after Pancreatectomy. Journal of the American College of Surgeons, 2014, 219, 875-886e1.	0.2	29

#	Article	IF	CITATIONS
127	Variations in Definition and Method of Retrieval of Complications Influence Outcomes Statistics after Pancreatoduodenectomy: Comparison of NSQIP with Non-NSQIP Methods. Journal of the American College of Surgeons, 2014, 219, 407-415.	0.2	18
128	Pancreatic Adenocarcinoma, Version 2.2014. Journal of the National Comprehensive Cancer Network: JNCCN, 2014, 12, 1083-1093.	2.3	307
129	Factors associated with recurrence in lymph node-negative gastric adenocarcinoma: Results from the U.S. Gastric Cancer Collaborative Journal of Clinical Oncology, 2014, 32, 80-80.	0.8	1
130	The effect of postoperative morbidity on survival after resection for gastric adenocarcinoma: Results from the U.S. Gastric Cancer Collaborative Journal of Clinical Oncology, 2014, 32, 5-5.	0.8	1
131	Next-generation sequencing in pancreatic cancer: Novel mutations and potential targets for therapy Journal of Clinical Oncology, 2014, 32, e15228-e15228.	0.8	Ο
132	The management of bariatric surgery complications. Surgery, 2013, 31, 569-573.	0.1	0
133	Cost benefit analysis of mesh reinforcement of stapled left pancreatectomy. Hpb, 2013, 15, 893-898.	0.1	8
134	The σ ₂ Receptor: A Novel Protein for the Imaging and Treatment of Cancer. Journal of Medicinal Chemistry, 2013, 56, 7137-7160.	2.9	131
135	The Case for Neoadjuvant Therapy in Locally Advanced Gastric Cancer. JAMA Surgery, 2013, 148, 361.	2.2	2
136	Comparison of WHO Classifications (2004, 2010), the Hochwald Grading System, and AJCC and ENETS Staging Systems in Predicting Prognosis in Locoregional Well-differentiated Pancreatic Neuroendocrine Tumors. American Journal of Surgical Pathology, 2013, 37, 853-859.	2.1	67
137	A Study of Zoledronic Acid as Neo-Adjuvant, Perioperative Therapy in Patients with Resectable Pancreatic Ductal Adenocarcinoma. Journal of Cancer Therapy, 2013, 04, 797-803.	0.1	26
138	The natural history of preoperative indeterminate pulmonary nodules in patients with resectable pancreatic adenocarcinoma Journal of Clinical Oncology, 2013, 31, 161-161.	0.8	0
139	Use of Multifunctional Sigma-2 Receptor Ligand Conjugates to Trigger Cancer-Selective Cell Death Signaling. Cancer Research, 2012, 72, 201-209.	0.4	41
140	Pancreatic Adenocarcinoma, Version 2.2012. Journal of the National Comprehensive Cancer Network: JNCCN, 2012, 10, 703-713.	2.3	248
141	Mesh Reinforcement of Pancreatic Transection Decreases Incidence of Pancreatic Occlusion Failure for Left Pancreatectomy. Annals of Surgery, 2012, 255, 1037-1042.	2.1	106
142	Presentation and Management of Gastrointestinal Stromal Tumors of the Duodenum: A Multi-Institutional Analysis. Annals of Surgical Oncology, 2012, 19, 3351-3360.	0.7	70
143	Multi-institutional analysis of pancreatic adenocarcinoma demonstrating the effect of diabetes status on survival after resection. Hpb, 2012, 14, 228-235.	0.1	46
144	Resection of Tumors of the Neck of the Pancreas with Venous Invasion: the "Whipple at the Splenic Artery (WATSA)―Procedure. Journal of Gastrointestinal Surgery, 2012, 16, 1048-1054.	0.9	42

#	Article	IF	CITATIONS
145	Unresectable Colorectal Cancer Synchronous Metastases: How to Manage the Primary Tumor. Current Colorectal Cancer Reports, 2012, 8, 118-122.	1.0	0
146	Long-Term Results of Resection of Adenocarcinoma of the Body and Tail of the Pancreas Using Radical Antegrade Modular Pancreatosplenectomy Procedure. Journal of the American College of Surgeons, 2012, 214, 46-52.	0.2	136
147	Fluorescent Derivatives of Ïf Receptor Ligand 1-Cyclohexyl-4-[3-(5-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)propyl]piperazine (PB28) as a Tool for Uptake and Cellular Localization Studies in Pancreatic Tumor Cells. Journal of Medicinal Chemistry, 2011. 54. 5858-5867.	2.9	35
148	DISPACT trial: what do we learn from equivalency?. Lancet, The, 2011, 377, 1470-1471.	6.3	2
149	Laparoscopic Versus Open Left Pancreatectomy. Annals of Surgery, 2011, 253, 975-980.	2.1	58
150	Influence of Obesity and Other Risk Factors on Survival Outcomes in Patients Undergoing Pancreaticoduodenectomy for Pancreatic Cancer. Pancreas, 2011, 40, 931-937.	0.5	59
151	Radiologic and intraoperative detection of need for mesenteric vein resection in patients with adenocarcinoma of the head of the pancreas. Hpb, 2011, 13, 633-642.	0.1	28
152	Ethical Management of Conflict of Interest: Proposed Standards for Academic Surgical Societies. Journal of the American College of Surgeons, 2011, 213, 677-682.	0.2	22
153	Analysis of 6,747 Pancreatic Neuroendocrine Tumors for a Proposed Staging System. Journal of Gastrointestinal Surgery, 2011, 15, 175-183.	0.9	40
154	A Technique of Gastrojejunostomy to Reduce Delayed Gastric Emptying after Pancreatoduodenectomy. Journal of Gastrointestinal Surgery, 2011, 15, 1468-1471.	0.9	13
155	Potential targets for pancreatic cancer immunotherapeutics. Immunotherapy, 2011, 3, 517-537.	1.0	57
156	Pancreatic Adenocarcinoma. Journal of the National Comprehensive Cancer Network: JNCCN, 2010, 8, 972-1017.	2.3	152
157	A Multicenter Analysis of Distal Pancreatectomy for Adenocarcinoma: Is Laparoscopic Resection Appropriate?. Journal of the American College of Surgeons, 2010, 210, 779-785.	0.2	309
158	A Better TRAIL Variant for Tumor Cell–Specific Targeting? – Response. Molecular Cancer Therapeutics, 2010, 9, 2854-2855.	1.9	0
159	A Genetically Encoded Multifunctional TRAIL Trimer Facilitates Cell-Specific Targeting and Tumor Cell Killing. Molecular Cancer Therapeutics, 2010, 9, 2142-2151.	1.9	19
160	To Mesh or Not to Mesh, That Is the Question. Archives of Surgery, 2009, 144, 899.	2.3	2
161	Circulating Mesothelin Protein and Cellular Antimesothelin Immunity in Patients with Pancreatic Cancer. Clinical Cancer Research, 2009, 15, 6511-6518.	3.2	68
162	Targeting AKT with the proapoptotic peptide, TATâ€CTMP: A novel strategy for the treatment of human pancreatic adenocarcinoma. International Journal of Cancer, 2009, 125, 942-951.	2.3	39

#	Article	IF	CITATIONS
163	Sepsis induces extensive autophagic vacuolization in hepatocytes: a clinical and laboratory-based study. Laboratory Investigation, 2009, 89, 549-561.	1.7	128
164	The effect of mesh reinforcement of a stapled transection line on the rate of pancreatic occlusion failure after distal pancreatectomy: review of a single institution's experience. Hpb, 2009, 11, 25-31.	0.1	39
165	Utility of the Gyrus open forceps in hepatic parenchymal transection. Hpb, 2009, 11, 258-263.	0.1	4
166	Laparoscopic Left Pancreatectomy: Complication Risk Score Correlates With Morbidity and Risk for Pancreatic Fistula. Annals of Surgical Oncology, 2009, 16, 2825-2833.	0.7	75
167	A prospective observational study examining quality of life in patients with malignant gastric outlet obstruction. American Journal of Surgery, 2009, 198, 92-99.	0.9	64
168	"Sideways― Results of Repair of Biliary Injuries Using a Policy of Side-To-Side Hepatico-Jejunostomy. Annals of Surgery, 2009, 249, 426-434.	2.1	87
169	Saline-Linked Surface Radiofrequency Ablation. Annals of Surgery, 2009, 250, 96-102.	2.1	8
170	The Accordion Severity Grading System of Surgical Complications. Annals of Surgery, 2009, 250, 177-186.	2.1	538
171	Laparoscopic gastric resection for gastrointestinal stromal tumors. Surgical Endoscopy and Other Interventional Techniques, 2008, 22, 2583-2587.	1.3	100
172	Unique site- and time-specific patterns of recurrence following resection of colorectal carcinoma hepatic metastases in patients staged by FDG-PET. Journal of Hepato-Biliary-Pancreatic Surgery, 2008, 15, 483-487.	2.0	6
173	Isolation of Right Main and Right Sectional Portal Pedicles for Liver Resection Without Hepatotomy or Inflow Occlusion. Journal of the American College of Surgeons, 2008, 206, 390-396.	0.2	26
174	A Prognostic System Applicable to Patients with Resectable Liver Metastasis from Colorectal Carcinoma Staged by Positron Emission Tomography with [18F]Fluoro-2-Deoxy-D-Glucose: Role of Primary Tumor Variables. Journal of the American College of Surgeons, 2008, 206, 857-868.	0.2	36
175	Establishing "Normal―Values for Liver Function Tests after Reconstruction of Biliary Injuries. Journal of the American College of Surgeons, 2008, 207, 705-709.	0.2	11
176	Human chorionic gonadotropin (hCG) interacts with lovastatin and ionizing radiation to modulate prostate cancer cell viability in vivo. Cancer Biology and Therapy, 2008, 7, 587-593.	1.5	3
177	Left-sided Pancreatectomy. Annals of Surgery, 2008, 248, 438-446.	2.1	362
178	Adjuvant Interferon-based Chemoradiation Followed By Gemcitabine for Resected Pancreatic Adenocarcinoma: A Single-Institution Phase II Study. Annals of Surgery, 2008, 248, 145-151.	2.1	54
179	TAT-Bim Induces Extensive Apoptosis in Cancer Cells. Annals of Surgical Oncology, 2007, 14, 1763-1771.	0.7	51
180	Radical Antegrade Modular Pancreatosplenectomy Procedure for Adenocarcinoma of the Body and Tail of the Pancreas: Ability to Obtain Negative Tangential Margins. Journal of the American College of Surgeons, 2007, 204, 244-249.	0.2	203

#	Article	IF	CITATIONS
181	Absorbable Mesh Reinforcement of a Stapled Pancreatic Transection Line Reduces the Leak Rate with Distal Pancreatectomy. Journal of Gastrointestinal Surgery, 2007, 11, 59-65.	0.9	88
182	Chemotherapy-Induced Normalization of FDG Uptake by Colorectal Liver Metastases Does Not Usually Indicate Complete Pathologic Response. Journal of Gastrointestinal Surgery, 2007, 11, 1112-1119.	0.9	90
183	Desmoplastic Melanoma: A Pathologically and Clinically Distinct Form of Cutaneous Melanoma. Annals of Surgical Oncology, 2005, 12, 207-213.	0.7	140
184	Caudate hepatectomy for cancer: A single institution experience with 150 patients. Journal of the American College of Surgeons, 2005, 200, 345-352.	0.2	68
185	Effect of Steatohepatitis Associated with Irinotecan or Oxaliplatin Pretreatment on Resectability of Hepatic Colorectal Metastases. Journal of the American College of Surgeons, 2005, 200, 845-853.	0.2	450
186	Hepatic Follicular Dendritic Cell Sarcoma Without Epstein-Barr Virus Expression. Archives of Pathology and Laboratory Medicine, 2005, 129, 1480-1483.	1.2	26
187	Jaundice Predicts Advanced Disease and Early Mortality in Patients With Gallbladder Cancer. Annals of Surgical Oncology, 2004, 11, 310-315.	0.7	197
188	Cutaneous Desmoplastic Melanoma. American Journal of Surgical Pathology, 2004, 28, 1518-1525.	2.1	192
189	A Single Heteroclitic Epitope Determines Cancer Immunity After Xenogeneic DNA Immunization Against a Tumor Differentiation Antigen. Journal of Immunology, 2003, 170, 5188-5194.	0.4	105
190	Xenogeneic DNA Immunization in Melanoma Models for Minimal Residual Disease. Journal of Surgical Research, 2002, 102, 137-143.	0.8	39
191	B cell deficient mice reject B16 melanoma via T cell mediated immunity that is not associated with autoimmunity. Journal of the American College of Surgeons, 2000, 191, S17-S18.	0.2	0
192	Effects of Preexisting Immunity on the Response to Herpes Simplex-Based Oncolytic Viral Therapy. Human Gene Therapy, 2000, 11, 2465-2472.	1.4	84
193	Coupling and Uncoupling of Tumor Immunity and Autoimmunity. Journal of Experimental Medicine, 1999, 190, 1717-1722.	4.2	232